Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Cash & Current Investments (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Cash & Current Investments for 8 consecutive years, with $230.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments fell 20.93% year-over-year to $230.9 million, compared with a TTM value of $230.9 million through Dec 2025, down 20.93%, and an annual FY2025 reading of $230.9 million, down 20.93% over the prior year.
  • Cash & Current Investments was $230.9 million for Q4 2025 at Arcturus Therapeutics Holdings, down from $235.4 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $466.8 million in Q1 2021 and bottomed at $55.0 million in Q2 2025.
  • Average Cash & Current Investments over 5 years is $321.4 million, with a median of $323.5 million recorded in 2023.
  • The sharpest move saw Cash & Current Investments skyrocketed 684.99% in 2021, then crashed 82.56% in 2025.
  • Year by year, Cash & Current Investments stood at $370.5 million in 2021, then increased by 5.77% to $391.9 million in 2022, then decreased by 11.45% to $347.0 million in 2023, then fell by 15.84% to $292.0 million in 2024, then dropped by 20.93% to $230.9 million in 2025.
  • Business Quant data shows Cash & Current Investments for ARCT at $230.9 million in Q4 2025, $235.4 million in Q3 2025, and $55.0 million in Q2 2025.